Abbott Laboratories (NYSE:ABT) Shares Sold by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 6.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,727 shares of the healthcare product maker's stock after selling 2,200 shares during the period. Nichols & Pratt Advisers LLP MA's holdings in Abbott Laboratories were worth $4,474,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ABT. Redwood Park Advisors LLC bought a new position in Abbott Laboratories during the 4th quarter worth about $25,000. NewSquare Capital LLC grew its holdings in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock worth $27,000 after acquiring an additional 105 shares in the last quarter. WealthTrak Capital Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $28,000. Rialto Wealth Management LLC purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $29,000. Finally, Wormser Freres Gestion purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at about $32,000. 75.18% of the stock is currently owned by institutional investors.

Abbott Laboratories Stock Down 0.6%

Shares of ABT stock traded down $0.82 during trading hours on Monday, reaching $133.62. 8,927,419 shares of the stock were exchanged, compared to its average volume of 6,167,685. The business's fifty day moving average is $133.29 and its two-hundred day moving average is $128.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $141.23. The firm has a market capitalization of $232.48 billion, a P/E ratio of 17.33, a P/E/G ratio of 2.55 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.38 billion. Abbott Laboratories had a net margin of 31.89% and a return on equity of 19.01%. As a group, research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be given a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.77%. The ex-dividend date of this dividend is Tuesday, July 15th. Abbott Laboratories's payout ratio is 30.61%.

Insider Transactions at Abbott Laboratories

In other news, Director Sally E. Blount sold 2,600 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the completion of the transaction, the director owned 34,058 shares in the company, valued at $4,415,960.28. This trade represents a 7.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.46% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on ABT. Jefferies Financial Group increased their price target on shares of Abbott Laboratories from $135.00 to $137.00 and gave the company a "hold" rating in a research report on Thursday, April 17th. Barclays increased their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an "overweight" rating in a research report on Thursday, April 17th. Morgan Stanley increased their price target on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research report on Thursday, April 17th. Raymond James Financial increased their price target on shares of Abbott Laboratories from $132.00 to $142.00 and gave the company an "outperform" rating in a research report on Thursday, April 17th. Finally, Royal Bank Of Canada increased their price target on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research report on Thursday, April 17th. Six analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $142.61.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.